Charlottesville-based biopharmaceutical company Adial Pharmaceuticals, Inc. is making strides in the clinical-stage development of therapeutics for addiction and related disorders. The company's flagship product, AD04, a selective serotonin-3 antagonist, is currently undergoing Phase III clinical trial for the treatment of alcohol use disorder. In addition to its work on addiction, Adial Pharmaceuticals is also developing drug candidates for non-opioid pain reduction and other diseases and disorders. Founded in 2010, Adial Pharmaceuticals is committed to creating innovative solutions to some of the most pressing health issues of our time.
Adial Pharmaceuticals, Inc's ticker is ADIL
The company's shares trade on the NASDAQ stock exchange
They are based in Charlottesville, Virginia
There are 1-10 employees working at Adial Pharmaceuticals, Inc
It is https://www.adialpharma.com/
Adial Pharmaceuticals, Inc is in the Healthcare sector
Adial Pharmaceuticals, Inc is in the Biotechnology industry
The following five companies are Adial Pharmaceuticals, Inc's industry peers: